Live Breaking News & Updates on Evaluable Patients

Stay updated with breaking news from Evaluable patients. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Protara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via Equity

Friday, Protara Therapeutics Inc (NASDAQ:TARA) shared data from three-month evaluable carcinoma in situ (CIS) patients treated across TARA-002 program, the company’s investigational cell-based therapy, in high-risk Non-Muscle Invasive Bladder Cancer (NMIBC), including Bacillus Calmette-Guérin (BCG)-Unresponsive, BCG-Experienced and BCG-Naïve patient populations. Data were derived from three-month evaluable NMIBC patients with CIS pooled across the company’s ADVANCED-1 Phase 1a, Phase 1b-expansio ....

Protara Therapeutics Inc , Non Muscle Invasive Bladder Cancer , Bacillus Calmette Gu , Protara Therapeutics , Common Warrant , Pre Funded Warrant , Stock Market Game , Benzinga Pro , Day Trial , Via Equity , Bladder Cancer , Protara Therapeutics , Evaluable Patients , Bacillus Calmette Guérin , Choline Chloride ,